Article
Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC.
International journal of oncology - 1 Oct 2020
Pan Chi, Duan Huijie, Wu Yinan, Zhu Chunpeng, Yi Chenghao, Duan Yin, Lu Demin, Guo Cheng, Wu Deqi, Wang Yanyan, Fu Xianhua, Xu Jing, Chen Yiding, Luo Meng, Tian Wei, Pan Tao, Xu Wenhong, Zhang Suzhan, Huang Jianjin
Abstract excerpt
Lung cancer has the highest incidence and mortality rates among the malignant tumor types worldwide. Platinum‑based chemotherapy is the main treatment for advanced non‑small‑cell lung cancer (NSCLC), and epidermal growth factor receptor‑tyrosine kinase inhibitors (EGFR‑TKIs) have greatly improved the survival of patients with EGFR‑sensitive mutations. However, there is no standard therapy for treating patients...
Topics
- Animals
- Antineoplastic Combined Chemotherapy Protocols
- Apoptosis
- Carcinoma, Non-Small-Cell Lung
- Cell Line, Tumor
- Cell Proliferation
- Cisplatin
- DNA-Activated Protein Kinase
- Drug Resistance, Neoplasm